EMA Sets Up Infrastructure to Support Real-World Monitoring of COVID-19 Vaccines

Article

The European Medicines Agency has set up an infrastructure to support real-world monitoring of the efficacy and safety of COVID-19 vaccines and treatments.

The European Medicines Agency (EMA) has set up an infrastructure to support real-world monitoring of the efficacy and safety of COVID-19 vaccines and treatments, it was revealed in a July 21, 2020 press release.

Underpinned by three contracts that EMA has signed with academic and private partners, the infrastructure will monitor vaccines being administered in a clinical setting as soon as they have been authorized. The information gained will support the safe and effective use of COVID-19 vaccines and medicines.

In May 2020, EMA commissioned the vaccine COVID-19 monitoring readiness (ACCESS) project, aimed at performing preparatory research into data sources and methods that can be used to monitor the safety, effectiveness, and coverage of COVID-19 vaccines in clinical practice. In June 2020, EMA contracted IQVIA to build a framework for the conduct of multicenter cohort studies on the use of medicines in COVID-19 patients. The project will be carried out in partnership with the European Health Data and Evidence Network (EHDEN) consortium.

The most recent contract, in mid-July 2020, has been agreed by EMA with Utrecht University and the University Medical Center Utrecht, which will be coordinators of the COVID-19 infection and medicines in pregnancy (CONSIGN) project. The aim of CONSIGN will be to collect data on the impact of COVID-19 in pregnancy to guide decision-making about vaccine indications, vaccination policies, and treatment options for COVID-19 in pregnant women.

More information on the contracts and other works being performed by EMA to support observational research and surveillance of COVID-19 treatments and vaccines can be found on the agency’s website.

Source: EMA

 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
David Fairen-Jimenez
Industry Outlook 2025: The Rising Prominence of AI in Pharma
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.